Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based SCM Pharma, a specialist in the global contract drug manufacturing market, will develop and manufacture an injectable neonatal product for Ireland-based BrePco BioPharma.
Subscribe to our email newsletter
The neonatal product is based on an established and approved inotropic agent, and will be used in clinical trial researching and treating critically ill premature babies suffering from hypotension.
BrePco has chosen the development and contract manufacturing organisation (CDMO) to initially produce development and clinical batches for eight clinical trial sites across Canada and Europe.
The goal of the trial is to develop a ready-to-use, licensed treatment for vulnerable preterm infants.
BrePco Biopharma co-founder and chairman Paul Breen said the project is progressing well and already the SCM team has shown its technical ability and commitment to meet the company’s deadlines and deliver the project to the available budget.
Under the European Commission’s Healthcare FP7 Program, BrePco along with 12 research partners across Ireland, Europe and Canada led by Cork University Maternity Hospital secured €5.6m for the project last year.